Legend Biotech to Present at the 44th Annual J.P. Morgan Healthcare Conference Life Science Investing
SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D Life Science Investing
Compass Therapeutics to Participate in the J.P. Morgan 2026 Healthcare Conference Life Science Investing
Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC Life Science Investing
Rakovina Therapeutics Management to Attend Partnering Meetings During JPM Week, January in San Francisco, California Life Science Investing
Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Life Science Investing
From Insulin Injections to Functional Cures: Regenerative Medicine Reshapes Diabetes Life Science Investing
Rain Enhancement Technologies Reports Early Positive Indications From First Two U.S. Installations Life Science Investing
ANKTIVA® with BCG Demonstrates 96% Survival from Bladder Cancer at Three Years with Median Survival Not Yet Reached in BCG-Unresponsive High-Grade Papillary-Only Non-Muscle Invasive Bladder Cancer Life Science Investing
Palvella Therapeutics Granted FDA Fast Track Designation for QTORIN 3.9% Rapamycin Anhydrous Gel rapamycin) for the Treatment of Angiokeratomas Life Science Investing
BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026
